ReviewJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG2020
COVID-19 and immunological regulations - from basic and translational aspects to clinical implications.
Review in Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Does prior exposure to immune checkpoint inhibitors treatment affect incidence and mortality of COVID-19 among the cancer patients: The systematic review and meta-analysis.International immunopharmacology · 2021Pooled it
- Association of gender and main comorbidities with expression of lncRNAs and mRNAs in COVID-19 patients.Journal, genetic engineering & biotechnology · 2026Article
- Association Between Periodontitis and SARS-CoV-2 Infection Severity: A Cross-Sectional Study in a Turkish Population.Oral health & preventive dentistry · 2025Article
- Expansion microscopy of neutrophil nuclear structure and extracellular traps.Biophysical reports · 2023Article
- [The impact of COVID-19 in a cohort of patients with systemic sclerosis].Revista medica del Instituto Mexicano del Seguro Social · 2023Article
- Omalizumab may protect allergic patients against COVID-19: A systematic review.The World Allergy Organization journal · 2023Review
- Treatment mechanism of immune triad from the repurposing drug against COVID-19.Translational medicine of aging · 2023Review
- Dapsone Lowers Neutrophil to Lymphocyte Ratio and Mortality in COVID-19 Patients Admitted to the ICU.International journal of molecular sciences · 2022Article
- Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.Allergy · 2022Observational
- The Impact of COVID-19 Pandemic on Medical Doctors' Work-Family Balance at German University Clinics.Healthcare (Basel, Switzerland) · 2022Article
- COVID-19-A Trigger Factor for Severe Immune-Mediated Thrombocytopenia in Active Rheumatoid Arthritis.Life (Basel, Switzerland) · 2022Article
- Platelets in the NETworks interweaving inflammation and thrombosis.Frontiers in immunology · 2022Review
- Dapsone, More than an Effective Neuro and Cytoprotective Drug.Current neuropharmacology · 2022Review
- Gender affects IL-23 serum levels in the hospitalized COVID-19 infected patients.American journal of clinical and experimental immunology · 2022Article
- Alarmins, COVID-19 and comorbidities.Annals of medicine · 2021Review
- Protection against COVID-19 in African population: Immunology, genetics, and malaria clues for therapeutic targets.Virus research · 2021Review
- Patient-blood management for COVID19 convalescent plasma therapy: relevance of affinity and donor-recipient differences in concentration of neutralizing antibodies.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2021Review
- The total number and mass of SARS-CoV-2 virions.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- The total number and mass of SARS-CoV-2 virions.medRxiv : the preprint server for health sciences · 2021Article
- The effect of environmental pollution on immune evasion checkpoints of SARS-CoV-2.Environmental toxicology and pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 14 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic caused by SARS-CoV-2 has far-reaching direct and indirect medical consequences. These include both the course and treatment of diseases. It is becoming increasingly clear that infections with SARS-CoV-2 can cause considerable immunological alterations, which particularly also affect pathogenetically and/or therapeutically relevant factors. Against this background we summarize here the current state of knowledge on the interaction of SARS-CoV-2/COVID-19 with mediators of the acute phase of inflammation (TNF, IL-1, IL-6), type 1 and type 17 immune responses (IL-12, IL-23, IL-17, IL-36), type 2 immune reactions (IL-4, IL-13, IL-5, IL-31, IgE), B-cell immunity, checkpoint regulators (PD-1, PD-L1, CTLA4), and orally druggable signaling pathways (JAK, PDE4, calcineurin). In addition, we discuss in this context non-specific immune modulation by glucocorticosteroids, methotrexate, antimalarial drugs, azathioprine, dapsone, mycophenolate mofetil and fumaric acid esters, as well as neutrophil granulocyte-mediated innate immune mechanisms. From these recent findings we derive possible implications for the therapeutic modulation of said immunological mechanisms in connection with SARS-CoV-2/COVID-19. Although, of course, the greatest care should be taken with patients with immunologically mediated diseases or immunomodulating therapies, it appears that many treatments can also be carried out during the COVID-19 pandemic; some even appear to alleviate COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.